Corza Medical manufactures and distributes surgical sutures (Quill®, Sharpoint®), fibrin sealants (TachoSil®), and reusable ophthalmic instruments (Katena®) across acute and non-acute surgical markets. The company is actively scaling sales capacity while adopting enterprise planning tools (SAP, Oracle, Kinaxis, Blue Yonder) alongside Salesforce and marketing automation—a shift toward supply-chain visibility and demand forecasting that aligns with their stated pain of enhancing global supply-chain efficiency and reducing manufacturing costs.
Notable leadership hires: Planning Director
Corza Medical operates a portfolio of surgical device and biosurgery brands serving surgeons, hospitals, distributors, and OEM partners globally. Founded in 2021, the company has grown to over 1,000 employees and manages manufacturing, quality, and distribution across multiple countries including the United States, Italy, Mexico, India, and Southeast Asia. The product portfolio spans barbed sutures for wound closure, ophthalmic knives and instruments, fibrin-based hemostatic agents, and OEM component solutions. Current priorities include new product development, expanding market presence in non-acute surgical settings, and strengthening supply-chain efficiency and working capital management.
Corza owns Quill® barbed sutures, Sharpoint® and Look™ surgical sutures, Katena® reusable ophthalmic instruments, Sharpoint ophthalmic knives, TachoSil® fibrin sealant matrix, Pearsalls, and FSSB OEM solutions.
Corza is adopting SAP, Oracle, Kinaxis, and Blue Yonder (demand planning), alongside Salesforce Marketing Cloud and Dynamics 365, indicating a major shift toward integrated supply-chain and enterprise resource planning.
Other companies in the same industry, closest in size